Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:activeDuring |
recombinant_Neisseria_meningitidis_proteins
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States |
| gptkbp:brand |
gptkb:MenB_vaccine
|
| gptkbp:category |
bacterial vaccine
|
| gptkbp:clinicalTrials |
multiple countries
Phase III recommended for high-risk groups |
| gptkbp:contraindication |
anaphylaxis
severe allergic reaction to any component |
| gptkbp:countryOfOrigin |
gptkb:Switzerland
|
| gptkbp:developedBy |
Novartis
|
| gptkbp:diseaseResistance |
deltoid muscle
conducted by health authorities for individuals at increased risk of meningococcal disease campaigns to educate about meningococcal disease licensed in multiple countries |
| gptkbp:dosageForm |
suspension for injection
|
| gptkbp:expansion |
recommended after initial series
|
| gptkbp:hasAccessTo |
available in many countries
|
| gptkbp:healthcare |
two doses
contributes to global health initiatives. important for proper administration |
| https://www.w3.org/2000/01/rdf-schema#label |
Bexsero
|
| gptkbp:incubationPeriod |
periodically reviewed by experts
|
| gptkbp:isTestedFor |
important for outbreak control
|
| gptkbp:lastProduced |
2013
|
| gptkbp:manufacturer |
gptkb:GSK
|
| gptkbp:marketedAs |
gptkb:MenB_vaccine
|
| gptkbp:marketSegment |
ongoing
|
| gptkbp:notable_player |
varies by region
global refrigerated subunit vaccine monitored through epidemiological studies history of severe allergic reaction adverse events reported approximately 80% in clinical trials ongoing studies for long-term efficacy reduces incidence of meningococcal B disease supported by public and private sectors two doses at least one month apart CDC_recommends_for_certain_age_groups |
| gptkbp:providesGuidelinesFor |
developed by health organizations
|
| gptkbp:reproduction |
liquid suspension
|
| gptkbp:route |
intramuscular injection
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
headache nausea fever pain at injection site |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:suitableFor |
from 2 months of age
|
| gptkbp:targets |
Neisseria meningitidis serogroup B
|
| gptkbp:team |
included_in_WHO's_list_of_essential_medicines
|
| gptkbp:usedFor |
prevention of meningococcal disease
|
| gptkbp:wasAffecting |
2015 in the US
provided to recipients |